Evidence map›Paper›PMID 39559354›Full record

ArticleFrontiers in immunology2024

Spleen tyrosine kinase: a novel pharmacological target for sepsis-induced cardiac dysfunction and multi-organ failure.

Chiara Verra, Maria Kerstin Paulmann, Jamila Wegener, Enrica Marzani, Gustavo Ferreira Alves, Massimo Collino, Sina Maren Coldewey, Christoph Thiemermann

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. PKM2: A gatekeeper in macrophage metabolic reprogramming.Journal of pharmaceutical analysis · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Bosutinib mitigates inflammation in experimental sepsis.European journal of clinical investigation · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chiara VerraCentre for Translational Medicine and Therapeutics, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom.
Maria Kerstin PaulmannDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.
Jamila WegenerDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.
Enrica MarzaniDepartment of Neurosciences "Rita Levi Montalcini", University of Turin, Turin, Italy.
Gustavo Ferreira AlvesPharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.
Massimo CollinoDepartment of Neurosciences "Rita Levi Montalcini", University of Turin, Turin, Italy.
Sina Maren ColdeweyDepartment of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany.
Christoph ThiemermannCentre for Translational Medicine and Therapeutics, William Harvey Research Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a systemic condition caused by a dysregulated host response to infection and often associated with excessive release of proinflammatory cytokines resulting in multi-organ failure (MOF), including cardiac dysfunction. Despite a number of effective supportive treatments (e.g. ventilation, dialysis), there are no specific interventions that prevent or reduce MOF in patients with sepsis. To identify possible intervention targets, we re-analyzed the publicly accessible Gene Expression Omnibus accession GSE131761 dataset, which revealed an increased expression of spleen tyrosine kinase (

Indexed as

Disease Models, AnimalMice, Inbred C57BLMultiple Organ FailureSepsisSyk KinaseAnimalsCytokinesHumansInflammasomesMaleMiceNiacinamideNLR Family, Pyrin Domain-Containing 3 ProteinProtein Kinase InhibitorsPyrimidinesSignal Transduction2-(7-(3,4-dimethoxyphenyl)imidazo(1,2-c)pyrimidin-5-ylamino)nicotinamideCytokinesInflammasomesNiacinamideNLR Family, Pyrin Domain-Containing 3 ProteinProtein Kinase InhibitorsPyrimidinesSyk KinaseSyk protein, mousecardiac dysfunctioncytokine stormMOFsepsisSYK

Identifiers

PMID39559354
PMCPMC11570271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.